Clinical Research Directory
Browse clinical research sites, groups, and studies.
NMDA Enhancement Combined With Omega-3 for Early Dementia
Sponsor: Chang Gung Memorial Hospital
Summary
In this 4-year proposed project, we will enroll 140 patients with aMCI or mild AD into a 24-week randomized, double-blind, placebo-controlled drug trial. All patients will be allocated randomly to one of two treatment groups for 24 weeks (n = 70 in each group) in a double-blind manner: \[1\] DAOIB + omega-3; \[2\] DAOIB + placebo. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB combined with omega-3 will yield better efficacy than placebo in improving the cognitive function, global functioning and quality of life in patients with aMCI or mild AD.
Official title: NMDA Enhancement Combined With Omega-3 Fatty Acids for the Treatment of Early Dementia
Key Details
Gender
All
Age Range
50 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2026-08
Completion Date
2028-03
Last Updated
2026-03-20
Healthy Volunteers
No
Conditions
Interventions
DAOIB+Omega-3
The omega-3 fatty acids dose will be adjusted every 8 weeks according to clinical evaluation.
DAOIB+Placebo
Placebo
Locations (1)
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan